Therefore, these findings together provide molecular and functional evidence for DCLK1-IN-1 as a potential immuno-oncology agent and further suggest that DCLK1 kinase activity should be investigated within this context in RCC and other tumors–especially given DCLK1-IN-1′s highly favorable pharmacokinetic properties and bioavailability [17]. Here, DCLK1 is linked to renal cell carcinoma.